Luba Greenwood and Ash Zenooz discuss the evolving biotech landscape, the impact of AI on drug discovery, the importance of using real-world evidence in drug development, and personal motivations for continuing efforts in the biotech field.
I teamed up with two health policy experts to explore the bull and bear case.
Christina Farr, Ash Zenooz, and Luba Greenwood are joined by Zeke Emanuel, a prominent oncologist, bioethicist, and influential voice in healthcare to discuss the impact of GLP-1 drugs, healthcare affordability, Trump's appointments, and AI in medicine. The second half of the episode was recorded a
Lessons learned after a strategy shift featuring Brightline CEO Naomi Allen and investor Alyssa Jaffee
Christina Farr and Ash Zenooz discuss the recent departures of prominent female CEOs from major healthcare companies and explore why progress in female leadership representation has been challenging in the healthcare industry.
That’s the question of the moment - and we explore it in-depth.
With Tom Cassels, who’s sat on plenty of boards as an independent director
I’m introducing a new series to ask experts in the space tough questions about topics of the moment
In this episode of Second Opinion, hosts Christina Farr, Ash Zenooz, and Luba Greenwood interview Rob Perez, founder of Life Science Cares, about his work bridging the biotech industry with poverty alleviation efforts.
Dr. Lloyd Minor, Dean of Stanford School of Medicine joins Christina Farr, Ash Zenooz, and Luba Greenwood to discuss the various transformative advancements and challenges in healthcare.
In this episode of Second Opinion, Christina Farr, Ash Zenooz, and Luba Greenwood discuss the integration and evaluation of digital tools in healthcare with guest Caroline Pearson from the Peterson Health Technology Institute.
